BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37958994)

  • 1. Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and Prostate-Specific Antigens in Prostate Cancer Cells.
    Akasaka Y; Hasei S; Ohata Y; Kanna M; Nakatsu Y; Sakoda H; Fujishiro M; Kushiyama A; Ono H; Matsubara A; Hinata N; Asano T; Yamamotoya T
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958994
    [No Abstract]   [Full Text] [Related]  

  • 2. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
    Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
    Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
    Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties.
    MacDonald AF; Bettaieb A; Donohoe DR; Alani DS; Han A; Zhao Y; Whelan J
    BMC Complement Altern Med; 2018 Jun; 18(1):188. PubMed ID: 29914450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPK Causes Cell Cycle Arrest in LKB1-Deficient Cells via Activation of CAMKK2.
    Fogarty S; Ross FA; Vara Ciruelos D; Gray A; Gowans GJ; Hardie DG
    Mol Cancer Res; 2016 Aug; 14(8):683-95. PubMed ID: 27141100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
    Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
    Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
    Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
    Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway.
    Hsu JL; Liu SP; Lee CC; Hsu LC; Ho YF; Huang HS; Guh JH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Oct; 387(10):979-90. PubMed ID: 25005758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis.
    Jung TY; Ryu JE; Jang MM; Lee SY; Jin GR; Kim CW; Lee CY; Kim H; Kim E; Park S; Lee S; Lee C; Kim W; Kim T; Lee SY; Ju BG; Kim HS
    Exp Mol Med; 2020 Nov; 52(11):1831-1844. PubMed ID: 33219302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
    Liu JL; Mao Z; Gallick GE; Yung WK
    Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.
    Mung KL; Eccleshall WB; Santio NM; Rivero-Müller A; Koskinen PJ
    Cell Commun Signal; 2021 Jun; 19(1):68. PubMed ID: 34193159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
    Shen M; Zhang Z; Ratnam M; Dou QP
    J Cell Physiol; 2014 Jun; 229(6):688-95. PubMed ID: 24129850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
    Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.
    Roca H; Varsos ZS; Pienta KJ
    Neoplasia; 2009 Dec; 11(12):1309-17. PubMed ID: 20019839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo.
    Chen D; Banerjee S; Cui QC; Kong D; Sarkar FH; Dou QP
    PLoS One; 2012; 7(10):e47186. PubMed ID: 23056607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.
    Zhou J; Huang W; Tao R; Ibaragi S; Lan F; Ido Y; Wu X; Alekseyev YO; Lenburg ME; Hu GF; Luo Z
    Oncogene; 2009 May; 28(18):1993-2002. PubMed ID: 19347029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.